KKR Genetic Disorder L.P., 10% Owner at BridgeBio Pharma, Inc. (BBIO), sold 3,450,000 shares at $60.47 ($208.6M) on 2021-02-17, disclosed to the SEC on 2021-02-17.
Open-market sale of $208.6M BBIO by 10% Owner. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.